{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:43:27Z","timestamp":1792813407033,"version":"4.5.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["5UM1AI126617-04"],"award-info":[{"award-number":["5UM1AI126617-04"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000245","name":"Michael Smith Foundation for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000245","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Gouvernement du Canada | Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-59810-2","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T09:15:29Z","timestamp":1747300529000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Autologous HIV-specific T cell therapy targeting conserved epitopes is well-tolerated in six adults with HIV: an open-label, single-arm phase 1 study"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0186-2975","authenticated-orcid":false,"given":"Danielle K.","family":"Sohai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8323-3085","authenticated-orcid":false,"given":"Michael D.","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0102-7892","authenticated-orcid":false,"given":"Patrick J.","family":"Hanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahmida","family":"Hoq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divyesh","family":"Kukadiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anushree","family":"Datar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3217-4713","authenticated-orcid":false,"given":"Dennis C.","family":"Copertino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8917-7280","authenticated-orcid":false,"given":"Christopher","family":"Lazarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chase D.","family":"McCann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Tanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abeer","family":"Shibli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haili","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8169-992X","authenticated-orcid":false,"given":"Pamela A.","family":"Chansky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Motta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0286-3946","authenticated-orcid":false,"given":"Tan T.","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget","family":"Dwyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talia M.","family":"Mota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winiffer D.","family":"Conce Alberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8157-1037","authenticated-orcid":false,"given":"Zabrina L.","family":"Brumme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie N.","family":"Kinloch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7065-3769","authenticated-orcid":false,"given":"Conrad Russell Y.","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynsay","family":"MacLaren Ehui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Henn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4470-1231","authenticated-orcid":false,"given":"R.","family":"Brad Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5140-9090","authenticated-orcid":false,"given":"Catherine M.","family":"Bollard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"key":"59810_CR1","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1126\/science.278.5341.1295","volume":"278","author":"D Finzi","year":"1997","unstructured":"Finzi, D. et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295\u20131300 (1997).","journal-title":"Science"},{"key":"59810_CR2","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1126\/science.278.5341.1291","volume":"278","author":"JK Wong","year":"1997","unstructured":"Wong, J. K. et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278, 1291\u20131295 (1997).","journal-title":"Science"},{"key":"59810_CR3","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1097\/QAD.0b013e328340a239","volume":"24","author":"TW Chun","year":"2010","unstructured":"Chun, T. W. et al. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS 24, 2803\u20132808 (2010).","journal-title":"AIDS"},{"key":"59810_CR4","doi-asserted-by":"publisher","unstructured":"Tebas, P. et al. CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication. J. Clin. Invest. 131 https:\/\/doi.org\/10.1172\/jci144486 (2021).","DOI":"10.1172\/jci144486"},{"key":"59810_CR5","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/8394","volume":"5","author":"D Finzi","year":"1999","unstructured":"Finzi, D. et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5, 512\u2013517 (1999).","journal-title":"Nat. Med."},{"key":"59810_CR6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/417095a","volume":"417","author":"DC Douek","year":"2002","unstructured":"Douek, D. C. et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 417, 95\u201398 (2002).","journal-title":"Nature"},{"key":"59810_CR7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1084\/jem.192.1.63","volume":"192","author":"V Appay","year":"2000","unstructured":"Appay, V. et al. HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J. Exp. Med. 192, 63\u201375 (2000).","journal-title":"J. Exp. Med."},{"key":"59810_CR8","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1038\/nm1482","volume":"12","author":"L Trautmann","year":"2006","unstructured":"Trautmann, L. et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat. Med. 12, 1198\u20131202 (2006).","journal-title":"Nat. Med."},{"key":"59810_CR9","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.immuni.2012.01.014","volume":"36","author":"L Shan","year":"2012","unstructured":"Shan, L. et al. Stimulation of HIV-1-Specific Cytolytic T Lymphocytes Facilitates Elimination of Latent Viral Reservoir after Virus Reactivation. Immunity 36, 491\u2013501 (2012).","journal-title":"Immunity"},{"key":"59810_CR10","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.4049\/jimmunol.165.2.1082","volume":"165","author":"JC Gea-Banacloche","year":"2000","unstructured":"Gea-Banacloche, J. C. et al. Maintenance of large numbers of virus-specific CD8+ T cells in HIV-infected progressors and long-term nonprogressors. J. Immunol. 165, 1082\u20131092 (2000).","journal-title":"J. Immunol."},{"key":"59810_CR11","doi-asserted-by":"publisher","first-page":"7828","DOI":"10.4049\/jimmunol.0803928","volume":"182","author":"A S\u00e1ez-Ciri\u00f3n","year":"2009","unstructured":"S\u00e1ez-Ciri\u00f3n, A. et al. Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses. J. Immunol. 182, 7828\u20137837 (2009).","journal-title":"J. Immunol."},{"key":"59810_CR12","doi-asserted-by":"publisher","first-page":"3916","DOI":"10.1182\/blood.V99.11.3916","volume":"99","author":"H Einsele","year":"2002","unstructured":"Einsele, H. et al. Infusion of cytomegalovirus (CMV)\u2013specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 99, 3916\u20133922 (2002).","journal-title":"Blood"},{"key":"59810_CR13","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/S0140-6736(03)14634-X","volume":"362","author":"KS Peggs","year":"2003","unstructured":"Peggs, K. S. et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 362, 1375\u20131377 (2003).","journal-title":"Lancet"},{"key":"59810_CR14","doi-asserted-by":"publisher","first-page":"4360","DOI":"10.1182\/blood-2010-01-262089","volume":"116","author":"T Feuchtinger","year":"2010","unstructured":"Feuchtinger, T. et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 116, 4360\u20134367 (2010).","journal-title":"Blood"},{"key":"59810_CR15","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","volume":"115","author":"HE Heslop","year":"2010","unstructured":"Heslop, H. E. et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115, 925\u2013935 (2010).","journal-title":"Blood"},{"key":"59810_CR16","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/S0140-6736(02)09672-1","volume":"360","author":"T Haque","year":"2002","unstructured":"Haque, T. et al. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 360, 436\u2013442 (2002).","journal-title":"Lancet"},{"key":"59810_CR17","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1182\/blood-2006-12-063008","volume":"110","author":"T Haque","year":"2007","unstructured":"Haque, T. et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 110, 1123\u20131131 (2007).","journal-title":"Blood"},{"key":"59810_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1200\/JCO.2011.39.8495","volume":"31","author":"V Icheva","year":"2013","unstructured":"Icheva, V. et al. Adoptive Transfer of Epstein-Barr Virus (EBV) Nuclear Antigen 1\u2013Specific T Cells As Treatment for EBV Reactivation and Lymphoproliferative Disorders After Allogeneic Stem-Cell Transplantation. J. Clin. Oncol. 31, 39\u201348 (2013).","journal-title":"J. Clin. Oncol."},{"key":"59810_CR19","doi-asserted-by":"publisher","first-page":"3309","DOI":"10.1182\/bloodadvances.2021004456","volume":"5","author":"JD Rubinstein","year":"2021","unstructured":"Rubinstein, J. D. et al. Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restricted. Blood Adv. 5, 3309\u20133321 (2021).","journal-title":"Blood Adv."},{"key":"59810_CR20","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13045-017-0469-0","volume":"10","author":"C Qian","year":"2017","unstructured":"Qian, C. et al. Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I\/II multicenter clinical trial. J. Hematol. Oncol. 10, 102 (2017).","journal-title":"J. Hematol. Oncol."},{"key":"59810_CR21","doi-asserted-by":"publisher","first-page":"5113","DOI":"10.1182\/blood-2013-02-486324","volume":"121","author":"AM Leen","year":"2013","unstructured":"Leen, A. M. et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 121, 5113\u20135123 (2013).","journal-title":"Blood"},{"key":"59810_CR22","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/infdis\/jiv022","volume":"212","author":"JA Sung","year":"2015","unstructured":"Sung, J. A. et al. Expanded cytotoxic T-cell lymphocytes target the latent HIV reservoir. J. Infect. Dis. 212, 258\u2013263 (2015).","journal-title":"J. Infect. Dis."},{"key":"59810_CR23","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/mt.2014.207","volume":"23","author":"S Lam","year":"2015","unstructured":"Lam, S. et al. Broadly-specific cytotoxic T cells targeting multiple HIV antigens are expanded from HIV+ patients: implications for immunotherapy. Mol. Ther. 23, 387\u2013395 (2015).","journal-title":"Mol. Ther."},{"key":"59810_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.omtm.2019.10.001","volume":"16","author":"S Patel","year":"2020","unstructured":"Patel, S. et al. HIV-Specific T Cells Can Be Generated against Non-escaped T Cell Epitopes with a GMP-Compliant Manufacturing Platform. Mol. Ther. Methods Clin. Dev. 16, 11\u201320 (2020).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"59810_CR25","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1016\/j.ymthe.2018.08.015","volume":"26","author":"JA Sung","year":"2018","unstructured":"Sung, J. A. et al. HIV-Specific, Ex Vivo Expanded T Cell Therapy: Feasibility, Safety, and Efficacy in ART-Suppressed HIV-Infected Individuals. Mol. Ther. 26, 2496\u20132506 (2018).","journal-title":"Mol. Ther."},{"key":"59810_CR26","doi-asserted-by":"publisher","first-page":"5391","DOI":"10.1182\/blood-2010-11-320226","volume":"117","author":"AG Chapuis","year":"2011","unstructured":"Chapuis, A. G. et al. HIV-specific CD8+ T cells from HIV+ individuals receiving HAART can be expanded ex vivo to augment systemic and mucosal immunity in vivo. Blood 117, 5391\u20135402 (2011).","journal-title":"Blood"},{"key":"59810_CR27","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1182\/blood.V81.8.2093.2093","volume":"81","author":"M Ho","year":"1993","unstructured":"Ho, M. et al. A phase 1 study of adoptive transfer of autologous CD8+ T lymphocytes in patients with acquired immunodeficiency syndrome (AIDS)-related complex or AIDS. Blood 81, 2093\u20132101 (1993).","journal-title":"Blood"},{"key":"59810_CR28","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/nm0297-205","volume":"3","author":"P Borrow","year":"1997","unstructured":"Borrow, P. et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat. Med. 3, 205\u2013211 (1997).","journal-title":"Nat. Med."},{"key":"59810_CR29","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/354453a0","volume":"354","author":"RE Phillips","year":"1991","unstructured":"Phillips, R. E. et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 354, 453\u2013459 (1991).","journal-title":"Nature"},{"key":"59810_CR30","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1634\/stemcells.18-4-230","volume":"18","author":"AK Sewell","year":"2000","unstructured":"Sewell, A. K., Price, D. A., Oxenius, A., Kelleher, A. D. & Phillips, R. E. Cytotoxic T Lymphocyte Responses to Human Immunodeficiency Virus: Control and Escape. Stem Cells 18, 230\u2013244 (2000).","journal-title":"Stem Cells"},{"key":"59810_CR31","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/mt.2016.3","volume":"24","author":"B Ondondo","year":"2016","unstructured":"Ondondo, B. et al. Novel Conserved-region T-cell Mosaic Vaccine With High Global HIV-1 Coverage Is Recognized by Protective Responses in Untreated Infection. Mol. Ther. 24, 832\u2013842 (2016).","journal-title":"Mol. Ther."},{"key":"59810_CR32","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/nm.2089","volume":"16","author":"DH Barouch","year":"2010","unstructured":"Barouch, D. H. et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat. Med 16, 319\u2013323 (2010).","journal-title":"Nat. Med"},{"key":"59810_CR33","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/nm.2108","volume":"16","author":"S Santra","year":"2010","unstructured":"Santra, S. et al. Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat. Med 16, 324\u2013328 (2010).","journal-title":"Nat. Med"},{"key":"59810_CR34","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nm1461","volume":"13","author":"W Fischer","year":"2007","unstructured":"Fischer, W. et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat. Med. 13, 100\u2013106 (2007).","journal-title":"Nat. Med."},{"key":"59810_CR35","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00281-006-0025-4","volume":"28","author":"G Makedonas","year":"2006","unstructured":"Makedonas, G. & Betts, M. R. Polyfunctional analysis of human t cell responses: importance in vaccine immunogenicity and natural infection. Springe. Semin. Immunopathol. 28, 209\u2013219 (2006).","journal-title":"Springe. Semin. Immunopathol."},{"key":"59810_CR36","doi-asserted-by":"publisher","first-page":"12937","DOI":"10.1128\/JVI.01004-14","volume":"88","author":"F Pereyra","year":"2014","unstructured":"Pereyra, F. et al. HIV control is mediated in part by CD8+ T-cell targeting of specific epitopes. J. Virol. 88, 12937\u201312948 (2014).","journal-title":"J. Virol."},{"key":"59810_CR37","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1097\/00126334-200407010-00005","volume":"36","author":"M Plana","year":"2004","unstructured":"Plana, M. et al. Relevance of HIV-1-specific CD4+ helper T-cell responses during structured treatment interruptions in patients with CD4+ T-cell nadir above 400\/mm3. J. Acquir Immune Defic. Syndr. 36, 791\u2013799 (2004).","journal-title":"J. Acquir Immune Defic. Syndr."},{"key":"59810_CR38","doi-asserted-by":"publisher","first-page":"7131","DOI":"10.4049\/jimmunol.0803658","volume":"182","author":"EL Turnbull","year":"2009","unstructured":"Turnbull, E. L. et al. Kinetics of expansion of epitope-specific T cell responses during primary HIV-1 infection. J. Immunol. 182, 7131\u20137145 (2009).","journal-title":"J. Immunol."},{"key":"59810_CR39","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1128\/JVI.79.2.860-868.2005","volume":"79","author":"OO Yang","year":"2005","unstructured":"Yang, O. O. et al. Human immunodeficiency virus type 1 clade B superinfection: evidence for differential immune containment of distinct clade B strains. J. Virol. 79, 860\u2013868 (2005).","journal-title":"J. Virol."},{"key":"59810_CR40","doi-asserted-by":"publisher","unstructured":"Sidney, J., Peters, B., Frahm, N., Brander, C. & Sette, A. HLA class I supertypes: a revised and updated classification. BMC Immunol. 9, 1 https:\/\/doi.org\/10.1186\/1471-2172-9-1 (2008).","DOI":"10.1186\/1471-2172-9-1"},{"key":"59810_CR41","doi-asserted-by":"publisher","first-page":"5528","DOI":"10.4049\/jimmunol.0803471","volume":"182","author":"C Motozono","year":"2009","unstructured":"Motozono, C., Yanaka, S., Tsumoto, K., Takiguchi, M. & Ueno, T. Impact of intrinsic cooperative thermodynamics of peptide-MHC complexes on antiviral activity of HIV-specific CTL. J. Immunol. 182, 5528\u20135536 (2009).","journal-title":"J. Immunol."},{"key":"59810_CR42","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/nm.4100","volume":"22","author":"JM Carlson","year":"2016","unstructured":"Carlson, J. M. et al. Impact of pre-adapted HIV transmission. Nat. Med. 22, 606\u2013613 (2016).","journal-title":"Nat. Med."},{"key":"59810_CR43","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41586-019-0898-8","volume":"566","author":"KM Bruner","year":"2019","unstructured":"Bruner, K. M. et al. A quantitative approach for measuring the reservoir of latent HIV-1 proviruses. Nature 566, 120\u2013125 (2019).","journal-title":"Nature"},{"key":"59810_CR44","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1038\/s41591-022-02023-7","volume":"28","author":"JD Gunst","year":"2022","unstructured":"Gunst, J. D. et al. Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b\/2a, randomized trial. Nat. Med. 28, 2424\u20132435 (2022).","journal-title":"Nat. Med."},{"key":"59810_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20442-3","volume":"12","author":"NN Kinloch","year":"2021","unstructured":"Kinloch, N. N. et al. HIV-1 diversity considerations in the application of the Intact Proviral DNA Assay (IPDA). Nat. Commun. 12, 165 (2021).","journal-title":"Nat. Commun."},{"key":"59810_CR46","doi-asserted-by":"publisher","first-page":"6103","DOI":"10.1128\/jvi.68.9.6103-6110.1994","volume":"68","author":"P Borrow","year":"1994","unstructured":"Borrow, P., Lewicki, H., Hahn, B. H., Shaw, G. M. & Oldstone, M. B. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68, 6103\u20136110 (1994).","journal-title":"J. Virol."},{"key":"59810_CR47","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.1128\/jvi.71.4.3120-3128.1997","volume":"71","author":"OO Yang","year":"1997","unstructured":"Yang, O. O. et al. Suppression of human immunodeficiency virus type 1 replication by CD8+ cells: evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms. J. Virol. 71, 3120\u20133128 (1997).","journal-title":"J. Virol."},{"key":"59810_CR48","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1126\/science.283.5408.1748","volume":"283","author":"M Carrington","year":"1999","unstructured":"Carrington, M. et al. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 283, 1748\u20131752 (1999).","journal-title":"Science"},{"key":"59810_CR49","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1073\/pnas.050567397","volume":"97","author":"SA Migueles","year":"2000","unstructured":"Migueles, S. A. et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc. Natl Acad. Sci. 97, 2709\u20132714 (2000).","journal-title":"Proc. Natl Acad. Sci."},{"key":"59810_CR50","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nature03113","volume":"432","author":"P Kiepiela","year":"2004","unstructured":"Kiepiela, P. et al. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 432, 769\u2013775 (2004).","journal-title":"Nature"},{"key":"59810_CR51","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1097\/QAD.0000000000000206","volume":"28","author":"M Mori","year":"2014","unstructured":"Mori, M. et al. HLA-B*35: 05 is a protective allele with a unique structure among HIV-1 CRF01_AE-infected Thais, in whom the B*57 frequency is low. AIDS 28, 959\u2013967 (2014).","journal-title":"AIDS"},{"key":"59810_CR52","doi-asserted-by":"publisher","first-page":"e1006629","DOI":"10.1371\/journal.ppat.1006629","volume":"13","author":"AS Thomas","year":"2017","unstructured":"Thomas, A. S. et al. T-cell responses targeting HIV Nef uniquely correlate with infected cell frequencies after long-term antiretroviral therapy. PLoS Pathog. 13, e1006629 (2017).","journal-title":"PLoS Pathog."},{"key":"59810_CR53","doi-asserted-by":"publisher","unstructured":"Stevenson, E. M. et al. HIV-specific T cell responses reflect substantive in vivo interactions with antigen despite long-term therapy. JCI Insight 6 https:\/\/doi.org\/10.1172\/jci.insight.142640 (2021).","DOI":"10.1172\/jci.insight.142640"},{"key":"59810_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32376-z","volume":"13","author":"EM Stevenson","year":"2022","unstructured":"Stevenson, E. M. et al. SARS CoV-2 mRNA vaccination exposes latent HIV to Nef-specific CD8(+) T-cells. Nat. Commun. 13, 4888 (2022).","journal-title":"Nat. Commun."},{"key":"59810_CR55","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.omtm.2019.07.008","volume":"15","author":"Y Xu","year":"2019","unstructured":"Xu, Y. et al. HIV-Specific T Cell Responses Are Highly Stable on Antiretroviral Therapy. Mol. Ther. Methods Clin. Dev. 15, 9\u201317 (2019).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"59810_CR56","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1056\/NEJMoa0802905","volume":"360","author":"G H\u00fctter","year":"2009","unstructured":"H\u00fctter, G. et al. Long-term control of HIV by CCR5 Delta32\/Delta32 stem-cell transplantation. N. Engl. J. Med. 360, 692\u2013698 (2009).","journal-title":"N. Engl. J. Med."},{"key":"59810_CR57","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/s41586-019-1027-4","volume":"568","author":"RK Gupta","year":"2019","unstructured":"Gupta, R. K. et al. HIV-1 remission following CCR5\u039432\/\u039432 haematopoietic stem-cell transplantation. Nature 568, 244\u2013248 (2019).","journal-title":"Nature"},{"key":"59810_CR58","doi-asserted-by":"publisher","first-page":"7597","DOI":"10.1182\/blood-2022-169223","volume":"140","author":"A Aribi","year":"2022","unstructured":"Aribi, A. et al. Durable Leukemia and HIV Remission without Antiviral Therapy Following an Allogeneic Hematopoietic Stem Cell Transplantation (alloHCT) Using a Donor with CCR5-\u039432\/\u039432 Homozygosity for an Acute Myeloid Leukemia (AML) Patient. Blood 140, 7597\u20137598 (2022).","journal-title":"Blood"},{"key":"59810_CR59","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.cell.2023.02.030","volume":"186","author":"J Hsu","year":"2023","unstructured":"Hsu, J. et al. HIV-1 remission and possible cure in a woman after haplo-cord blood transplant. Cell 186, 1115\u20131126.e1118 (2023).","journal-title":"Cell"},{"key":"59810_CR60","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41591-023-02213-x","volume":"29","author":"B-EO Jensen","year":"2023","unstructured":"Jensen, B.-E. O. et al. In-depth virological and immunological characterization of HIV-1 cure after CCR5\u039432\/\u039432 allogeneic hematopoietic stem cell transplantation. Nat. Med. 29, 583\u2013587 (2023).","journal-title":"Nat. Med."},{"key":"59810_CR61","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41409-020-01018-7","volume":"56","author":"J Allred","year":"2021","unstructured":"Allred, J. et al. Chimeric antigen receptor T-cell therapy for HIV-associated diffuse large B-cell lymphoma: case report and management recommendations. Bone Marrow Transplant. 56, 679\u2013682 (2021).","journal-title":"Bone Marrow Transplant."},{"key":"59810_CR62","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.1002\/cncr.32411","volume":"125","author":"JS Abramson","year":"2019","unstructured":"Abramson, J. S. et al. Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma. Cancer 125, 3692\u20133698 (2019).","journal-title":"Cancer"},{"key":"59810_CR63","doi-asserted-by":"publisher","unstructured":"Abbasi, A. et al. Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis. J. Hematol. Oncol. 13, 1 https:\/\/doi.org\/10.1186\/s13045-019-0838-y (2020).","DOI":"10.1186\/s13045-019-0838-y"},{"key":"59810_CR64","doi-asserted-by":"publisher","unstructured":"Peluso, M. J. et al. Differential decay of intact and defective proviral DNA in HIV-1-infected individuals on suppressive antiretroviral therapy. JCI Insight 5 https:\/\/doi.org\/10.1172\/jci.insight.132997 (2020).","DOI":"10.1172\/jci.insight.132997"},{"key":"59810_CR65","doi-asserted-by":"publisher","first-page":"e1007991","DOI":"10.1371\/journal.ppat.1007991","volume":"15","author":"J Grau-Exp\u00f3sito","year":"2019","unstructured":"Grau-Exp\u00f3sito, J. et al. Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T subpopulations. PLoS Pathog. 15, e1007991 (2019).","journal-title":"PLoS Pathog."},{"key":"59810_CR66","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1182\/blood-2018-07-863654","volume":"132","author":"LP McLaughlin","year":"2018","unstructured":"McLaughlin, L. P. et al. EBV\/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. Blood 132, 2351\u20132361 (2018).","journal-title":"Blood"},{"key":"59810_CR67","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jcyt.2020.08.006","volume":"23","author":"CA Lazarski","year":"2021","unstructured":"Lazarski, C. A. et al. Identification of new cytokine combinations for antigen-specific T-cell therapy products via a high-throughput multi-parameter assay. Cytotherapy 23, 65\u201376 (2021).","journal-title":"Cytotherapy"},{"key":"59810_CR68","doi-asserted-by":"publisher","first-page":"7588","DOI":"10.1128\/JVI.00734-12","volume":"86","author":"RM Lynch","year":"2012","unstructured":"Lynch, R. M. et al. The development of CD4 binding site antibodies during HIV-1 infection. J. Virol. 86, 7588\u20137595 (2012).","journal-title":"J. Virol."},{"key":"59810_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34171-2","volume":"13","author":"M Ros\u00e1s-Umbert","year":"2022","unstructured":"Ros\u00e1s-Umbert, M. et al. Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8(+) T cell immunity. Nat. Commun. 13, 6473 (2022).","journal-title":"Nat. Commun."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59810-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59810-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59810-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T10:03:48Z","timestamp":1747303428000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59810-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["59810"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-59810-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,15]]},"assertion":[{"value":"4 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.M.B. is on the Board of Directors of Cabaletta Bio and was the scientific co-founder and scientific advisory board member of Catamaran Bio, has stock in Repertoire Immune Medicines and serves on the data and safety monitoring board (DSMB) of the Swedish Orphan Biovitrum (SOBI). PJH is an advisor or member of on an advisory board of Autolomous, CARTx, Celleknos, Cipla, March Biosciences, MFX, and Y Innovations. M.D.K. is an author for Elsevier (Uptodate) and has received research funding from Chiesi Pharmaceuticals. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4510"}}